GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study

J Infect Dis. 2005 Mar 1;191(5):678-85. doi: 10.1086/427559. Epub 2005 Jan 28.

Abstract

Background: The effect that GB virus C (GBV-C) coinfection has on human immunodeficiency virus type 1 (HIV-1) disease progression is controversial and therefore was studied in 326 homosexual men from the prospective Amsterdam Cohort Studies who had an accurately estimated date of HIV-1 seroconversion and were followed up for a median period of 8 years.

Methods: A first plasma sample, obtained shortly after HIV-1 seroconversion, and a last plasma sample, obtained before 1996, were tested for GBV-C RNA and envelope protein-2 antibodies. The effect that GBV-C has on HIV-1 disease progression was studied by use of time-dependent Cox proportional-hazards models with adjustment for baseline variables and time-updated HIV-1 RNA and CD4(+) cell count.

Results: Men who lost GBV-C RNA between collection of the first sample and collection of the last sample had a nearly 3-fold-higher risk of HIV-1 disease progression than did men who had never had GBV-C RNA. This effect became much smaller after adjustment for time-updated CD4(+) cell count.

Conclusion: Rather than a positive effect of GBV-C RNA presence, a negative effect of GBV-C RNA loss on HIV-1 disease progression was found, which disappeared after adjustment for time-updated CD4(+) cell count. We therefore hypothesize that GBV-C RNA persistence depends on the presence of a sufficient number of CD4(+) cells--and that the CD4(+) cell decrease associated with HIV-1 disease progression is a cause, not a consequence, of GBV-C RNA loss.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • Disease Progression
  • Flaviviridae Infections / complications
  • Flaviviridae Infections / immunology
  • Flaviviridae Infections / physiopathology*
  • GB virus C / genetics
  • GB virus C / isolation & purification*
  • HIV Antibodies / blood
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • HIV Infections / physiopathology*
  • HIV-1* / immunology
  • Humans
  • Male
  • Proportional Hazards Models
  • Prospective Studies
  • RNA, Viral / blood
  • Time Factors

Substances

  • Anti-HIV Agents
  • HIV Antibodies
  • RNA, Viral